openPR Logo
Press release

Metastatic Liver Cancer Pipeline Outlook Report 2024 (Updated)

06-07-2024 01:40 AM CET | Health & Medicine

Press release from: ABNewswire

Metastatic Liver Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Metastatic-Liver-Cancer Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic-Liver-Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Metastatic Liver Cancer Pipeline Report

* DelveInsight's Metastatic Liver Cancer pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Metastatic Liver Cancer treatment.
* The leading Metastatic Liver Cancer Companies such as Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
* Promising Metastatic Liver Cancer Therapies such as ThermoDox Registered (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG Registered -1, AV-299, RO7119929, Tocilizumab, and others.
* May 2024:- Alpha Tau Medical Ltd- A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Liver Metastases. This study is a Prospective, Open label, one arm, single center study to evaluate the feasibility and safety of Diffusing Alpha Radiation Emitters for the treatment of Liver Metastases.
* May 2024:- Eureka Therapeutics Inc.- An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3). The trial is suitable for adult subjects ( greater than or equal to 18 years of age) diagnosed with GPC3-positive HCC, who have failed or not tolerated at least two (2) different anti-HCC systemic agents.

Explore our comprehensive Metastatic Liver Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Metastatic Liver Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Liver Cancer Overview

The liver is a common site for metastases from many cancer types. Cancers that spread to the liver most often are colorectal cancer as well as with breast, esophageal, stomach, pancreatic, lung, kidney and melanoma skin cancers. Cancers spread to the liver because the liver filters most of the blood from the rest of the body, and when cancer cells break away from a primary cancer, they often enter and travel through the bloodstream. Sometimes the discovery of metastatic liver cancer is the first indication that a person has cancer. Often, the first symptoms are vague. They include weight loss, poor appetite, and sometimes fever.

Metastatic-Liver-Cancer Emerging Drugs

* exoASO STAT6: Codiak BioSciences

exoASO Trademark -STAT6 is an exosome therapeutic candidate engineered using our engEx Trademark Platform to overexpress Codiak's novel protein scaffold, PTGFRN, to selectively target uptake in M2 polarized tumor-associated macrophages. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

* STP 705: Sirnaomics

STP705, is a dual TGF-Ss1/COX-2 inhibitor. TGF-Ss1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development. STP705 leverages our locally administered PNP formulation for direct administration to diseased tissue. STP705 has received U.S. orphan drug designation for the treatment of certain hepatocellular carcinomas and liver fibrosis, including: primary sclerosing cholangitis (PSC), cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

* ONCR 177: Oncorus

ONCR-177, our lead product candidate, is an intratumorally administered Herpes Simplex Virus (HSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4). Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Metastatic-Liver-Cancer.

Dive into our Metastatic Liver Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Metastatic Liver Cancer Treatment Therapies [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic Liver Cancer Therapeutics Assessment

There are approx. 20+ key companies which are developing the therapies for Metastatic-Liver-Cancer. The companies which have their Metastatic-Liver-Cancer drug candidates in the most advanced stage, i.e. phase I include, Oncorus.

DelveInsight's Metastatic Liver Cancer Pipeline Report covers around 25+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Download the Metastatic Liver Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Metastatic Liver Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Metastatic-Liver-Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Metastatic Liver Cancer Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Dive into our detailed Metastatic Liver Cancer Pipeline Report to discover ground breaking advancements shaping the future of cancer treatment @ Metastatic Liver Cancer Products, Companies, and Unmet Needs [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Metastatic Liver Cancer Pipeline Report

* Coverage- Global
* Metastatic Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Metastatic Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Metastatic Liver Cancer Companies- Oncorus, Sirnaomics, Codiak BioSciences, Sorrento Therapeutics, Inc., RemeGen Co., Ltd., Taiho Pharmaceutical Co., Ltd., Amarin Corporation, Eureka Therapeutics, Medivir AB, AstraZeneca, Amal Therapeutics, Boehringer Ingelheim, and others.
* Metastatic Liver Cancer Therapies- ThermoDox Registered (LTLD), NV1020, Combretastatin A1 Diphosphate (OXi4503), Talaporfin sodium (LS11), CRS-100, EndoTAG Registered -1, AV-299, RO7119929, Tocilizumab, and others.

Gain valuable insights into emerging therapies and innovations with our Metastatic Liver Cancer Pipeline Report @ Metastatic Liver Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views [https://www.delveinsight.com/sample-request/metastatic-liver-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Metastatic-Liver-Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Metastatic-Liver-Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ONCR 177: Oncorus
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name :Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Metastatic-Liver-Cancer Key Companies
* Metastatic-Liver-Cancer Key Products
* Metastatic-Liver-Cancer- Unmet Needs
* Metastatic-Liver-Cancer- Market Drivers and Barriers
* Metastatic-Liver-Cancer- Future Perspectives and Conclusion
* Metastatic-Liver-Cancer Analyst Views
* Metastatic-Liver-Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=metastatic-liver-cancer-pipeline-outlook-report-2024-updated]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metastatic Liver Cancer Pipeline Outlook Report 2024 (Updated) here

News-ID: 3529751 • Views:

More Releases from ABNewswire

Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Platform
Adapts.ai Redefines Software Maintenance and Modernization with GenAI-Powered Pl …
October 10, 2025 - In an era where digital transformation defines competitive advantage, Adapts.ai is emerging as a game-changer in enterprise application modernization and AI-driven digital transformation services. The platform leverages next-generation GenAI technology to simplify software maintenance, accelerate legacy code modernization, and empower engineering teams with intelligent automation. Adapts addresses one of the most pressing challenges in modern software engineering - navigating outdated, poorly documented, and complex legacy codebases. Traditional
A Journey Across Oceans and Generations:
A Journey Across Oceans and Generations: "From Germany With Love" Uncovers One F …
Julie Anne Brion never set out to write a history book. What she did want was to understand where she came from, and maybe, just maybe, help others feel a little less lost in their own search for belonging. The result is her newest book, From Germany With Love: Mit Liebe aus Deutschland , a deeply personal look at one family's journey from the heart of Europe to the promise
New Book from Immigration Attorney Shares Practical Guidance for Securing a U.S. Green Card
New Book from Immigration Attorney Shares Practical Guidance for Securing a U.S. …
New York, NY - Immigrants working toward permanent residency in the United States now have a new guide to help them through the process. Anne Zeitoun-Sedki, an immigration attorney with more than 15 years of hands-on experience, whose YouTube channel has attracted millions of views worldwide, has published a book that simplifies the path to a U.S. green card. The book draws on Zeitoun-Sedki's years of representing individuals and families from
Kinghelm Antennas Power OBD Applications in Smart and New Energy Vehicles
Kinghelm Antennas Power OBD Applications in Smart and New Energy Vehicles
Kinghelm, a leading RF and microwave technology company, provides high-performance antennas and connectors for OBD systems in smart and new energy vehicles. Together with partners Slkor Semiconductor and Avant Electronics, Kinghelm delivers integrated solutions for GPS/BDS positioning, Bluetooth/Wi-Fi transmission, and intelligent vehicle connectivity. Image: https://www.abnewswire.com/upload/2025/10/0790f023c90e731790a4ec80533af9ea.jpg Automotive OBD Products and Application Scenarios As intelligent connected vehicles become increasingly mainstream, On-Board Diagnostics (OBD) systems have emerged as a vital component for ensuring driving safety, emissions

All 5 Releases


More Releases for Liver

Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Liver Metastases Treatment Market Size By 2025? The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health. ● Product Name - LivCare
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production